(312) 275-5850 9-5pm CST
0 CART $0.00
Your shopping cart is empty.
CIA Medical Google Customer Reviews – Central Infusion Alliance
CIA Medical BBB Accredited A+ Business – Central Infusion Alliance
CIA Medical Digicert EV Secure – Central Infusion Alliance
Menu

Baxter 2B0793 - Dobutamine Hydrochloride, 5% Dextrose Injection, 1000 mg/ 250 ml (4000 mcg/ml), Viaflex Plastic Container, Liquid Premix, 18/cs (Rx) (Continental US Only, Excluding IN and ND) (Product Access Restricted. Check with your sales rep to verify eligibility)

Baxter # 2B0793 - Dobutamine Hydrochloride, 5% Dextrose Injection, 1000 mg/ 250 ml (4000 mcg/ml), Viaflex Plastic Container, Liquid Premix, 18/cs (Rx) (Continental US Only, Excluding IN and ND) (Product Access Restricted. Check with your sales rep to verify eligibility)
Part Number Baxter 2B0793
SKU Number CIA8043448
Sell Unit CASE
Ships Within Special Order
List Price $797.07
Enter a valid quantity
Product Description

Baxter 2B0793 - Dobutamine Hydrochloride, 5% Dextrose Injection, 1000 mg/ 250 ml (4000 mcg/ml), Viaflex Plastic Container, Liquid Premix, 18/cs (Rx) (Continental US Only, Excluding IN and ND) (Product Access Restricted. Check with your sales rep to verify eligibility)

Baxter 2B0793 DOBUTamine Hydrochloride in 5% Dextrose Injection

Dobutamine Hydrochloride in 5% Dextrose Injection, 250 mg/250 mL

Dobutamine Hydrochloride in 5% Dextrose Injection is a sterile, nonpyrogenic solution of Dobutamine Hydrochloride, USP and Dextrose, USP in Water for Injection, USP. Dobutamine hydrochloride is chemically designated as (+/-)-4-[2-[[3-(p-hydroxyphenyl)-1-methylpropyl]amino]ethyl]-pyrocatechol hydrochloride. It is a synthetic catecholamine. Dextrose Hydrous, USP is chemically designated as D-Glucopyranose monohydrate. Structural formulas are shown below:

Composition Dobutamine Hydrochloride in 5% Dextrose Injection
Dobutamine (mg/Container)Dobutamine (mcg/mL)Dextrose Hydrous, USP (g/L)Osmolarity (mOsmol/L) (calc)pHkcal/L
250 mg/250 mL1000502593.5
(2.5 to 5.5)
170
500 mg/250 mL2000502663.5
(2.5 to 5.5)
170

1000 mg/250 mL

4000502803.5
(2.5 to 5.5)
170

Dobutamine Hydrochloride in 5% Dextrose Injection is intended for intravenous use only. It contains no antimicrobial agents. The pH is adjusted with sodium hydroxide and/or hydrochloric acid. Sodium bisulfite is added as a stabilizer. The solution is intended for single use only. When smaller doses are required, the unused portion should be discarded. Composition, osmolarity, pH and caloric content

This VIAFLEX PLUS plastic container is fabricated from a specially formulated polyvinyl chloride (PL 2207 Plastic). VIAFLEX containers, including VIAFLEX PLUS containers, are made of flexible plastic and are for parenteral use. VIAFLEX PLUS on the container indicates the presence of a drug additive in a drug vehicle. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million; however, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.

Baxter 2B0793 Indications and Usage

Dobutamine Hydrochloride in 5% Dextrose Injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions.

Whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-AMP-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. In controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-AMP-dependent inotropes were consistently associated with increased risks of hospitalization and death. Patients with NYHA Class IV symptoms appeared to be at particular risk.

Baxter 2B0793 Contraindications

Dobutamine Hydrochloride in 5% Dextrose Injection is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine.

Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

Related Products